Beyondspring (BYSI) vs. Editas Medicine (EDIT) Head to Head Comparison

Beyondspring (NASDAQ: BYSI) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.

Valuation and Earnings

This table compares Beyondspring and Editas Medicine’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Beyondspring N/A N/A -$12.01 million N/A N/A
Editas Medicine $13.73 million 134.32 -$120.32 million ($2.98) -13.20

Beyondspring has higher earnings, but lower revenue than Editas Medicine.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Beyondspring and Editas Medicine, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beyondspring 0 0 4 0 3.00
Editas Medicine 1 4 5 0 2.40

Beyondspring currently has a consensus price target of $54.50, indicating a potential upside of 99.63%. Editas Medicine has a consensus price target of $45.60, indicating a potential upside of 15.91%. Given Beyondspring’s stronger consensus rating and higher possible upside, analysts plainly believe Beyondspring is more favorable than Editas Medicine.

Insider and Institutional Ownership

1.2% of Beyondspring shares are owned by institutional investors. Comparatively, 72.4% of Editas Medicine shares are owned by institutional investors. 19.4% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


This table compares Beyondspring and Editas Medicine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Beyondspring N/A N/A N/A
Editas Medicine -876.49% -61.92% -32.60%


Beyondspring beats Editas Medicine on 6 of the 10 factors compared between the two stocks.

Beyondspring Company Profile

BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company’s BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company’s IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.

Editas Medicine Company Profile

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with's FREE daily email newsletter.

Leave a Reply